The detection of NRAS gene mutation in lymphatic endothelial cells of GLA and KLA not only provides a more specific means for the diagnosis of LM but also provides a potential opportunity for the development of targeted therapy for current drug-resistant lesions. Here, NRAS is linked to lymphangioma.